

Arnaud Fekkar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2372524/publications.pdf>

Version: 2024-02-01

22
papers

1,349
citations

471509

17
h-index

677142

22
g-index

24
all docs

24
docs citations

24
times ranked

2347
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. <i>Science Immunology</i> , 2023, 8, .	11.9	35
2	Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 180-190.	10.7	161
3	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2200413119.	7.1	110
4	Occurrence of Candidemia in Patients with COVID-19 Admitted to Five ICUs in France. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 678.	3.5	11
5	Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 307-317.	5.6	131
6	Clinical Origin and Species Distribution of <i>Fusarium</i> spp. Isolates Identified by Molecular Sequencing and Mass Spectrometry: A European Multicenter Hospital Prospective Study. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 678.	3.5	11
7	Hospital Outbreak of Fluconazole-Resistant <i>Candida parapsilosis</i> : Arguments for Clonal Transmission and Long-Term Persistence. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	42
8	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. <i>Science Immunology</i> , 2021, 6, .	11.9	357
9	Etest ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent <i>Candida</i> spp. to Triazoles and Amphotericin B and <i>Aspergillus</i> spp. to Caspofungin: Further Assessment of Modal Variability. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0109321.	3.2	12
10	COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it?. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1376-1378.	6.0	33
11	Identification of Molds with Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry: Performance of the Newly Developed MSI-2 Application in Comparison with the Bruker Filamentous Fungi Database and MSI-1. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0129921.	3.9	18
12	Antifungal Susceptibility of 182 <i>Fusarium</i> Species Isolates from 20 European Centers: Comparison between EUCAST and Gradient Concentration Strip Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0149521.	3.2	9
13	COVID-19-Associated Pulmonary Aspergillosis, Fungemia, and Pneumocystosis in the Intensive Care Unit: a Retrospective Multicenter Observational Cohort during the First French Pandemic Wave. <i>Microbiology Spectrum</i> , 2021, 9, e0113821.	3.0	32
14	Ibrutinib induces multiple functional defects in the neutrophil response against <i>Aspergillus fumigatus</i> . <i>Haematologica</i> , 2020, 105, 478-489.	3.5	41
15	Fungal Infection during COVID-19: Does <i>Aspergillus</i> Mean Secondary Invasive Aspergillosis?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 902-903.	5.6	26
16	COVID-19-related Respiratory Failure and Lymphopenia Do Not Seem Associated with Pneumocystosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1734-1736.	5.6	27
17	Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient. <i>Emerging Infectious Diseases</i> , 2020, 26, 1636-1637.	4.3	118
18	Multi-centric evaluation of the online MSI platform for the identification of cryptic and rare species of <i>Aspergillus</i> by MALDI-TOF. <i>Medical Mycology</i> , 2019, 57, 962-968.	0.7	40

#	ARTICLE	IF	CITATIONS
19	Aspergillus PCR in Bronchoalveolar Lavage Fluid for the Diagnosis and Prognosis of Aspergillosis in Patients With Hematological and Non-hematological Conditions. <i>Frontiers in Microbiology</i> , 2018, 9, 1877.	3.5	26
20	Treatment of Cyclosporin A retains host defense against invasive pulmonary aspergillosis in a non-immunosuppressive murine model by preserving the myeloid cell population. <i>Virulence</i> , 2017, 8, 1744-1752.	4.4	13
21	Calcineurin inhibitors impair neutrophil activity against <i>Aspergillus fumigatus</i> in allogeneic hematopoietic stem cell transplant recipients. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 860-868.	2.9	29
22	Breakthrough invasive mould infections in patients treated with caspofungin. <i>Journal of Infection</i> , 2012, 64, 424-429.	3.3	63